Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Accenture
US Army
Medtronic
Teva
Fish and Richardson
Merck
Julphar
Mallinckrodt

Generated: May 20, 2018

DrugPatentWatch Database Preview

OXYTROL Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Oxytrol, and when can generic versions of Oxytrol launch?

Oxytrol is a drug marketed by Allergan Sales Llc and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-two patent family members in twenty countries.

The generic ingredient in OXYTROL is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.
Drug patent expirations by year for OXYTROL
Pharmacology for OXYTROL
Synonyms for OXYTROL
(+/-)-oxybutynin
(+/-)-OXYBUTYNIN(Hydrochloride form)
1508-65-2 (hydrochloride)
27815-EP2269989A1
27815-EP2275420A1
27815-EP2280008A2
27815-EP2298767A1
27815-EP2314587A1
4-(Diethylamino)-2-butynyl .alpha.-phenylcyclohexaneglycolate
4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester
4-(Diethylamino)-2-butynyl cyclohexyl(hydroxy)phenylacetate #
4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate
4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate
4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate
4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate
4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenyl-acetate
4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
4-Diethylamino-2-butinyl alpha-cyclohexylmandelat
4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate
4-diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
5633-20-5
633O205
AB0013281
AB2000274
AC-2153
AC1L1ILV
AK162584
AKOS015896242
AN-14276
Anturol
Anturol (TN)
API0007236
AX8146542
BDBM50165019
Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester
BPBio1_000214
BRD-A65013509-003-03-8
BSPBio_000194
C-20821
C07360
CC-33425
CCG-205005
CCRIS 1923
CHEBI:7856
CHEMBL1231
CS-2255
Cyclohexaneglycolic acid, .alpha.-phenyl-, 4-(diethylamino)-2-butynyl ester
Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester
Cystrin
D00465
D0F5LH
DB01062
Ditropan
Ditropan Xl
Ditropan;Lyrinel XL;Oxytrol
DR001867
DTXSID0023406
FT-0082890
FT-0603679
GTPL359
HSDB 3270
HY-B0267
I06-2117
K-9978
kentera
KS-00000GVI
KS-5221
L000923
Lopac0_000923
LP048773
LS-28714
Lyrinel XL
MCULE-3407007074
MFCD00865252
MLS006010052
MolPort-003-849-741
MRF-0000601
NCGC00015767-03
NCGC00015767-04
NCGC00015767-06
NCGC00015767-07
NCGC00015767-09
NCGC00089795-02
O222
OR285581
Oxibutinina
Oxibutinina [INN-Spanish]
Oxibutyninum
Oxybutinin
oxybutynin
Oxybutynin (Ditropan)
Oxybutynin (USAN/INN)
Oxybutynin [USAN:INN:BAN]
Oxybutynin Base
oxybutynin topical gel
Oxybutynin transdermal
Oxybutynin transdermal patch
OXYBUTYNIN, Oxybutynin chloride
Oxybutynine
Oxybutynine [INN-French]
Oxybutyninum
Oxybutyninum [INN-Latin]
Oxytrol (TN)
Pollakisu
Prestwick0_000287
Prestwick1_000287
Prestwick2_000287
Prestwick3_000287
s1754
SBI-0050898.P002
SC-26752
SCHEMBL2992
SMR001550466
SPBio_002413
ST24048863
transdermal patch
XIQVNETUBQGFHX-UHFFFAOYSA-N

US Patents and Regulatory Information for OXYTROL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 OTC Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 OTC Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for OXYTROL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for OXYTROL
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe 2008-08-19

Non-Orange Book US Patents for OXYTROL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,241,662 Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy ➤ Sign Up
7,029,694 Compositions and methods for transdermal oxybutynin therapy ➤ Sign Up
7,087,241 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Baxter
Fuji
Queensland Health
Boehringer Ingelheim
Citi
Julphar
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.